The Perkin-elmer Corporation

Berkeley Lights, Inc.

Onyx Therapeutics, Inc.

Bruker Cellular Analysis, Inc.

Intrabiotics Pharmaceuticals, Inc.

Peggy A Radel

Mark P White

Randall D Lowe, Jr

Kevin T Chapman

Jason M McEwen

Xiaohua Wang

Gang F Wang

Minha Park

Xiao Guan Radstrom

Guido K Stadler

George L Fox

Steven Menchen

John H Musser

Scott C Benson

Mark Stephen Smyth

Robert I Lehrer

Craig M Crews

Guy J Laidig

Kevin D Shenk

Krishna G Upadhya

Weiguo Zhen

Conway C Chang

Ronald T Borchardt

Joe Y Lam

Barry A Bunin

Jie Chen

Jason M Mcewen

Jr Randall D Lowe

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Compounds for enzyme inhibition

Dibenzorhodamine compounds having the structure ##STR1## are disclosed, including nitogen- and aryl-substituted forms thereof. In addition, intermediates useful for synthesizing such compounds are disclosed, such intermediates having the structure ##STR2## In Formula I, R.sub.1 is H or ##STR3## wherein Y is H, lower alkyl, lower alkene, lower alkyne, aromatic, phenyl, polycyclic aromatic, heterocycle, water-solubilizing group, or linking group, including substituted forms thereof. When R.sub.1 is H, the C-12-bonded nitrogen and the C-12 and C-13 carbons form a first ring structure having from 4 to 7 members, and/or the C-12-bonded nitrogen and the C-11 and C-12 carbons form a second ring structure having from 5 to 7 members. The compounds of Formula I further include aryl- and nitrogen-substituted forms thereof. The invention further includes energy transfer dyes comprising the dibenzorhodamine compounds, nucleosides labeled with the dibenzorhodamine compounds, and nucleic acid analysis methods employing the dibenzorhodamine compounds.

Dibenzorhodamine dyes

The invention is directed to antimicrobial peptides related to naturally-occurring protegrin peptides, and methods of using the peptides in a variety of contexts, including the treatment or prevention of infections, and diseases related thereto.

Threonine-containing protegrins

Growing community of inventors

Berkeley, CA, United States of America

Peggy A Radel